Status In progress
Process STA
ID number 937

Provisional Schedule

Expected publication 25 July 2018

Project Team

Project lead Donna Barnes

Email enquiries

Consultees

Companies sponsors Roche
Others Department of Health
  NHS England
  NHS North Durham CCG
  NHS Stockport CCG
  Welsh Government
Patient carer groups Brain and Spine Foundation
  Disability Rights UK
  Leonard Cheshire Disability
  Multiple Sclerosis National Therapy Centres
  Multiple Sclerosis Society
  Multiple Sclerosis Trust
  Multiple Sclerosis-UK
  Muslim Council of Britain
  Neurological Alliance
  Shift.ms
  South Asian Health Foundation
  Specialised Healthcare Alliance
  Sue Ryder
Professional groups Association of British Neurologists
  British Geriatrics Society
  British Neuropathological Society
  Institute of Neurology
  Primary Care Neurology Society
  Royal College of General Practitioners
  Royal College of Nursing
  Royal College of Pathologists
  Royal College of Physicians
  Royal Pharmaceutical Society
  Royal Society of Medicine
  Therapists in MS
  UK Clinical Pharmacy Association
  UK Multiple Sclerosis Specialist Nurse Association

Commentators

Comparator companies Bayer (interferon beta 1b)
  Biogen Idec (daclizumab, dimethyl fumarate, interferon beta 1a, natalizumab, peginterferon beta 1a)
  Genzyme (alemtuzumab, teriflunomide)
  Merck Serono (interferon beta 1a)
  Novartis (interferon beta 1b, fingolimod)
  Teva UK (glatiramer acetate)
General commentators All Wales Therapeutics and Toxicology Centre
  Allied Health Professionals Federation
  Board of Community Health Councils in Wales
  British National Formulary
  Care Quality Commission
  Department of Health, Social Services and Public Safety for Northern Ireland
  Healthcare Improvement Scotland
  Medicines and Healthcare Products Regulatory Agency
  Multiple Sclerosis Society Wales
  National Association of Primary Care
  National Pharmacy Association
  Neurological Alliance of Scotland
  NHS Alliance
  NHS Commercial Medicines Unit
  NHS Confederation
  Scottish Medicines Consortium
  Wales Neurological Alliance
  Welsh Health Specialised Services Committee
Relevant research groups Brain Research Trust
  British Neurological Research Trust
  Cochrane Multiple Sclerosis Group
  MRC Clinical Trials Unit
  National Institute for Health Research
  National Hospital for Neurology and Neurosurgery

Timeline

Key events during the development of the guidance:

Date Update
02 October 2017 Invitation to participate
23 June 2017 Following on from advice received from the company this appraisal has been rescheduled. Therefore, we now anticipate that the appraisal will begin during late September 2017 when we will write to you about how you can get involved. The deadline for submissions is expected in approximately late November 2017.
24 January 2017 Draft scope documents
05 December 2016 Referral

For further information on how we develop guidance, please see our page about NICE technology appraisal guidance